<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732560</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-8RW</org_study_id>
    <nct_id>NCT03732560</nct_id>
  </id_info>
  <brief_title>A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US</brief_title>
  <official_title>A Retrospective Observational Study Comparing Nivolumab + Ipilimumab Combination vs. Nivolumab Monotherapy as First Line Treatment of Metastatic PD-L1 Positive Melanoma in the US</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to describe patient characteristics, treatment outcomes and adverse
      events for patients with metastatic melanoma testing positive for PD-L1 expression treated
      first line (1L) with either nivolumab and ipilimumab in combination (NIVO + IPI) or nivolumab
      (NIVO) monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">October 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) from Advanced Diagnosis</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) from Advanced Diagnosis</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) from 1L Therapy Initiation</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) from Index Date</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Therapy Response</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
    <description>Best response (complete response, CR or partial response, PR) will be measured from the start of index treatment to progression or recurrence. Outcome will be reported as the percent of patients achieving best response from the total population of patients in a study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Best Therapy Response</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Peak Response</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE's</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAE's</measure>
    <time_frame>Minimum follow up 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Patients undergoing treatment with nivolumab and ipilimumab</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing treatment with nivolumab</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Patients undergoing treatment with nivolumab</arm_group_label>
    <arm_group_label>Patients undergoing treatment with nivolumab and ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult metastatic melanoma patients with a positive PD-L1 expression level (above 1%)
        treated with nivolumab or nivolumab+ipilimumab in the first line setting in the US between
        Oct 1, 2015 and July 1, 2017
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years or older

          -  First advanced of diagnosis of metastatic/Stage IV) melanoma

          -  Tested for PD-L1 expression with a tumor proportion score (TPS) greater than or equal
             to 1% (Phase 1 data collection)

          -  Initiating a first line of therapy during the index period between October 1, 2015
             through July 1, 2017

          -  Medical history available for medical chart abstraction from date of diagnosis through
             most recent or current therapy (defined as end of data collection period)

        Exclusion Criteria:

          -  Patients enrolled in a cancer treatment-related clinical trial prior to first line
             therapy initiation for metastatic/Stage IV) melanoma

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parsippany</city>
        <state>New Jersey</state>
        <zip>07054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

